Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.

Saved in:
Bibliographic Details
Title: Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.
Authors: Alexander KM; Stanford Amyloid Center, Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, California., Davis MK; Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada., Akinboboye O; Laurelton Heart Specialists, Queens Heart Institute, Rosedale, New York, New York., Berk J; Boston Medical Center, Boston University, Boston, Massachusetts., Bhatt K; Division of Cardiology of the Department of Medicine at Emory University, Emory Healthcare, Atlanta, Georgia., Cappelli F; Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy., Cuddy SAM; Heart and Vascular Center, Brigham and Women's Hospital, Boston, Massachusetts., Fontana M; National Amyloidosis Centre, Division of Medicine, University College London, London, United Kingdom., Garcia-Pavia P; Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain., Gillmore JD; Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, University College London, London, United Kingdom., Griffin JM; Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston., Grodin JL; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas., Judge DP; Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston., Khouri MG; Division of Cardiology, Department of Medicine, Duke University Health System, Durham, North Carolina., Lam K; Western Australia Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Western Australia, Australia., Masri A; Division of Cardiology, Oregon Health & Science University, Portland., Maurer MS; Department of Medicine, Columbia University Irving Medical Center, New York, New York., Obici L; Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Ruberg FL; Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, Massachusetts., Sarswat N; Division of Cardiovascular Medicine, University of Chicago Medicine, Chicago, Illinois., Shah K; Pauley Heart Center, Virginia Commonwealth University, Richmond., Soman P; Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Stern L; Department of Cardiology, Smidt Heart Institute, Cedars Sinai, Los Angeles, California., Wright R; Pacific Heart Institute and Providence, St. John's Health Center, Santa Monica, California., Xiong K; BridgeBio, San Francisco, California., Cao X; BridgeBio, San Francisco, California., Lystig T; BridgeBio, San Francisco, California., Tamby JF; BridgeBio, San Francisco, California., Castaño A; BridgeBio, San Francisco, California., Katz L; BridgeBio, San Francisco, California., Sinha U; BridgeBio, San Francisco, California., Fox JC; BridgeBio, San Francisco, California., Solomon SD; Heart and Vascular Center, Brigham and Women's Hospital, Boston, Massachusetts., Grogan M; Cardiovascular Medicine, Mayo Clinic Rochester, Minnesota.
Source: JAMA cardiology [JAMA Cardiol] 2026 Jan 01; Vol. 11 (1), pp. 57-67.
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101676033 Publication Model: Print Cited Medium: Internet ISSN: 2380-6591 (Electronic) NLM ISO Abbreviation: JAMA Cardiol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2380-6591
DOI:10.1001/jamacardio.2025.4477